New York, NY -- (ReleaseWire) -- 02/18/2013 --Cannabis Science, Inc. (OTC:CBIS) has drugs in the development stage to treat ailments not being considered by its mainstream competitors. The company is located in Colorado were marijuana is legal for both medicinal and recreational use.
CBIS primarily focus on developing medications to treat autism, blood pressure, cancer and cancer side effects, HIV, and other illnesses, including general health maintenance.
The November elections counted 18 states electing to legalize marijuana for medicinal purposes and two states decriminalizing recreational use.
Cannabis Science, Inc., a development stage company, engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products.
Find out where CBIS could be headed by getting the trend analysis report here: http://www.wallstreetreport.net/market-scan/?symbol=CBIS
RegenBioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTC Pink: BMSN) announced last week the filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company's HemaXellerate I™ stem cell drug in patients with drug-refractory aplastic anemia.
HemaXellerate I™ is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies.
Bio-Matrix Scientific Group, Inc. (BMSN) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs.
Find out more on BMSN here: http://www.wallstreetreport.net/market-scan/?symbol=BMSN
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit: http://www.wallstreetreport.net/disclaimer-2/
WALL STREET REPORT